Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials

Medicina Clinica

Volumn 139, Issue 10, 2012, Pages 421-429

  Catalá López, Ferrán ^a,b,c   Corrales, Inmaculada ^c,d   Martín Serrano, Gloria ^c   Tobías, Aurelio ^e   Calvo, Gonzalo ^f  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^c Department of Medicines for Veterinary Use   (Spain)

^d Quality Agency of the Spanish National Health System   (Spain)

^e INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Eltrombopag; Meta analysis; Randomized controlled trials; Romiplostim; Thrombocytopenia; Thromboembolism; Thrombosis

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR;

AGONIST; ARTICLE; COCHRANE LIBRARY; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; BENZOATES; HEMATOLOGIC AGENTS; HUMANS; HYDRAZINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RISK FACTORS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPOIETIN;

EID: 84866898636     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2011.11.023     Document Type: Article

References (37)

1. R. Stasi, J. Bosworth, E. Rhodes, M.S. Shannon, F. Willis, and E.C. Gordon-Smith Thrombopoietic agents Blood Rev 24 2010 179 190
2. J. de la Rubia, E. Contreras, and J. Del Río-Garma Thrombotic thrombocytopenic purpura Med Clin (Barc) 136 2011 534 540
3. European Medicines Agency. Summary of the European Public Assessment Report (EPAR) for Nplate. EMEA/H/C/000942-II/0010/G (last update February 2011). Available at: < http://www.ema.europa.eu/ > [accessed July 2011].
4. European Medicines Agency. Summary of the European Public Assessment Report (EPAR) for Revolade. EMEA/H/C/001110-II/0005 (last update June 2011). Available at: < http://www.ema.europa.eu/ > [accessed July 2011].
5. G. Molineux, and A. Newland Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside Br J Haematol 150 2010 9 20
6. H.M. Rinder, J.E. Schuster, C.S. Rinder, C. Wang, H.J. Schweidler, and B.R. Smith Correlation of thrombosis with increased platelet turnover in thrombocytosis Blood 91 1998 1288 1294
7. A.I. Schafer Essential thrombocythemia and thrombocytosis M.A. Lichtman, E. Beutler, T.J. Kipps, U. Slegsohn, K. Kaushansky, J.T. Prchal, Williams hematology 7th ed. 2006 McGraw-Hill Medical New York
8. D.J. Kuter, M. Rummel, R. Boccia, B.G. Macik, I. Pabinger, and D. Selleslag Romiplostim or standard of care in patients with immune thrombocytopenia N Engl J Med 363 2010 1889 1899
9. G. Cheng, M.N. Saleh, C. Marcher, S. Vasey, B. Mayer, and M. Aivado Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Lancet 377 2011 393 402 [Epub 2010 Aug 23]
10. J.B. Bussel, D.J. Kuter, J.N. George, R. McMillan, L.M. Aledort, and G.T. Conklin AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP N Engl J Med 355 2006 1672 1681
11. T.B. Gernsheimer, J.N. George, L.M. Aledort, M.D. Tarantino, U. Sunkara, and D. Matthew Guo Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) J Thromb Haemost 8 2010 1372 1382
12. Higgins JPT, Green S. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane handbook for systematic reviews of interventions 5.1.0 [Web document]. The Cochrane Collaboration, 2011. Available at: < http://www.cochrane-handbook.org/ > [accessed July 2011].
13. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
14. G. Urrútia, and X. Bonfill PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses Med Clin (Barc) 135 2010 507 511
15. A. Laupacis, D.L. Sackett, and R.S. Roberts An assessment of clinically useful measures of the consequences of treatment N Engl J Med 318 1988 1728 1733
16. J. Nuovo, J. Melnikow, and D. Chang Reporting number needed to treat and absolute risk reduction in randomized controlled trials JAMA 287 2002 2813 2814
17. J.L. Hutton Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials Br J Haematol 146 2009 27 30
18. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
19. C.B. Begg, and M. Mazumdar Operating characteristic of a rank correlation test for publication bias Biometrics 50 1994 1088 1091
20. M. Egger, G. Davey, M. Schenider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
21. D.J. Kuter, J.B. Bussel, R.M. Lyons, V. Pullarkat, T.B. Gernsheimer, and F.M. Senecal Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Lancet 371 2008 395 403
22. GlaxoSmithKline. Eltrombopag studies. Summary report for study SB-497115/003. Number UM2007/00146/00. Available at: < http://www.gsk- clinicalstudyregister.com/ > [accessed January 2011].
23. A. Kellum, A. Jagiello-Gruszfeld, I.N. Bondarenko, R. Patwardhan, C. Messam, and Y. Mostafa Kamel A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors Curr Med Res Opin 26 2010 2339 2346
24. J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, L. Kovaleva, and B. Meddeb Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura N Engl J Med 357 2007 2237 2247
25. GlaxoSmithKline. Eltrombopag studies. Summary report for study TRA102537 (number. UM2008/00027/02). Available at: < http://www.gsk- clinicalstudyregister.com/ > [accessed January 2011].
26. GlaxoSmithKline. Eltrombopag studies. Summary report for study TRA108109. Available at: < http://www.gsk-clinicalstudyregister.com/ > [accessed January 2011].
27. GlaxoSmithKline. Eltrombopag studies. Summary report for study TPL104054 (number YM2009/00203/00). Available at: < http://www.gsk- clinicalstudyregister.com/ > [accessed January 2011].
28. M. Nieto, G. Calvo, I. Hudson, P. Feldschreiber, D. Brown, and C.C. Lee The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP) Haematologica Jun 2011 [Epub ahead of print]
29. P.P. Glasziou, S. Shepperd, and J. Brassey Can we rely on the best trial? A comparison of individual trials and systematic reviews BMC Med Res Methodol 10 2010 23
30. S.D. Halpern, J.H. Karlawish, and J.A. Berlin The continuing unethical conduct of underpowered clinical trials JAMA 288 2002 358 362
31. S. Day Evidence-based medicine and rare diseases Adv Exp Med Biol 686 2010 41 53
32. J. Thachil, T. Callaghan, and V. Martlew Thromboembolic events are not uncommon in patients with immune thrombocytopenia Br J Haematol 150 2010 496 497
33. S. Zelcer, and J.B. Bussel Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series J Thromb Haemost 1 Suppl. 1 2003 P1169
34. K. Kojouri, S.K. Vesely, D.R. Terrell, and J.N. George Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess longterm platelet count responses, prediction of response, and surgical complications Blood 104 2004 2623 2634
35. Y. Zeng, X. Duan, J. Xu, and X. Ni TPO receptor agonist for chronic idiopathic thrombocytopenic purpura Cochrane Database Syst Rev 7 2011 CD008235
36. US Food and Drug Administration (FDA): MedWatch The FDA Safety Information - Safety Alerts For Human Medicinal Products. "Promacta (eltrombopag): Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease". Available at: < http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm > [accessed July 2011].
37. GlaxoSmithKline. Dear Healthcare Professional Letter of May 4, 2010 for Promacta (eltrombopag): Notification Of Safety Information: Portal Venous System Thromboses in a Study of Patients With Chronic Liver Disease (ELEVATE). Available at: < http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM211801.pdf > [accessed July 2011].